Response to: 'Failed oral immunotherapy should be considered as a risk factor for fatal anaphylaxis, and omalizumab treatment considered'

Affiliations

• ¹ Department of Health Sciences, University of Florence, Florence, 50139, Italy.
• ² Department of Life Sciences and Public Health, Pediatric Allergy Unit, University Foundation Policlinico Gemelli IRCCS Catholic University of the Sacred Heart, Rome, Italy. [email protected].
• ³ Pediatric Unit, Department of Mother and Child Health, Salesi Children's Hospital, Ancona, 60123, Italy.
• ⁴ Allergy Unit, Meyer Children's Hospital IRCCS, Florence, 50139, Italy.
• ⁵ Pediatric Hospital Giovanni XXIII, Pediatric and Emergency Department, AOU Policlinic of Bari, Bari, 70126, Italy.
• ⁶ Pediatric Unit, Department of Surgical Sciences, Dentistry, Gynecology and Pediatrics, University of Verona, Verona, 37126, Italy.
• ⁷ Pediatric Department, Latisana-Palmanova Hospital, Azienda Sanitaria Universitaria Friuli Centrale, Udine, 33100, Italy.
• ⁸ Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, 27100, Italy.
• ⁹ Pediatric Clinic, Fondazione IRCCS Policlinico San Matteo, Pavia, 27100, Italy.
• ¹⁰ Translational Research in Pediatric Specialties Area, Division of Allergy, Bambino Gesù Children's Hospital, IRCCS, Rome, 00165, Italy.
• ¹¹ Allergy Unit, Department of Pediatrics, AOU Policlinico Gaetano Martino, Messina, 98124, Italy.
• ¹² Department of Woman, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Naples, 80138, Italy.